CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
Ovarian Cancer Videos
Potential Risks of Genetic Testing in Ovarian Cancer
Peter Levonian, MS, senior genetic counselor, Stanford Medicine, discusses the potential risks of genetic testing in ovarian cancer.
Neoadjuvant Chemo VS Cytoreductive Surgery in OC
Panelists review the criteria for choosing neoadjuvant chemotherapy, and comment on the role of cytoreductive surgery for advanced ovarian cancer (OC).
Advanced Ovarian Cancer: Optimizing Therapy Based on Current Data
Dr. Westin on Emerging PARP Inhibitors in Ovarian Cancer
Shannon N. Westin, MD, MPH, clinical investigator, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses PARP inhibitors being tested in clinical trials.
Dr. Markman Discusses the Future of Treatment for Ovarian Cancer
Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care
for Gynecological Cancers, discusses the future of treatment for patients with ovarian cancer.
Dr. Nguyen on Treatment Approaches for Patients With Advanced Ovarian Cancer
Trung Nguyen, DO, MBA, clinical assistant professor, Obstetrics and Gynecology, Gynecologic Oncology, Stanford Medicine, discusses treatment approaches for patients with advanced ovarian cancer.
Dr. Dorigo on Immunotherapy in Ovarian Cancer
Oliver Dorigo, MD, PhD, associate professor of Obstetrics and Gynecology, Stanford University Medical Center, Stanford Medicine, discusses the use of immunotherapy in the treatment of patients with ovarian cancer.
Dr. Berek Discusses the Impact of PARP Inhibitors on Ovarian Cancer
Jonathan S. Berek, MD, MMS, Laurie Kraus Lacob Professor, Stanford University School of Medicine, director, Stanford Women’s Cancer Center, senior advisor, Stanford Cancer Institute, discusses the impact of PARP inhibitors on the treatment landscape of ovarian cancer.
The Importance of Genetic Testing Following a Diagnosis of Ovarian Cancer
Peter Levonian, MS, senior genetic counselor, Stanford Medicine, discusses the importance of genetic testing following a diagnosis of ovarian cancer.
Dr. Karam on Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Ovarian Cancer
Amer Karam, MD, associate clinical professor, Gynecologic Oncology, Stanford Hospital, director, Robotic Surgery and Outreach, Division of Gynecologic Oncology, Stanford Medicine, discusses primary debulking surgery versus neoadjuvant chemotherapy in the treatment of patients with ovarian cancer.
Dr. Powell on Tumor Mutational Burden in Ovarian Cancer
Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses tumor mutational burden (TMB) in ovarian cancer.
Next Page >>
FDA Approval in NSCLC, Priority Review in SCLC, 2018 SABCS Highlights, and More
Jagannath Discusses Building on the Biology of Multiple Myeloma
Real-World irAEs May Be Higher Than Trial Data Indicate
De-Escalation Possible in Curative Setting for HER2+ Breast Cancer
Expert Discusses Lymphedema Treatment and Challenges in Breast Cancer
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.